The relationship between telomere length and cancer survival has been widely studied. To gain a deeper insight, we reviewed the published studies. A total of 29 studies evaluated telomere length in the peripheral blood; 22 studies evaluated telomere length in the tumor tissue. First, in the peripheral blood studies, for solid tumor patients with shortened telomere length, the combined hazard ratios (HRs) for mortality and tumor progression were 1.21 (95%CI, 1.10–1.32) and 1.71 (95%CI, 1.37–2.13), respectively. Meanwhile, in hematology malignancy, the combined HRs for mortality and tumor progression were 2.83 (95%CI, 2.14–3.74) and 2.65 (95%CI, 2.18–3.22), respectively. Second, in the studies that use tumor tissue, for patients with shortened telomeres, the combined HRs for mortality and tumor progression were 1.26 (95%CI, 0.95–1.66) and 1.65 (95%CI, 1.26–2.15), respectively. In the studies that calculate the telomere length ratios of tumor tissue to adjacent normal mucosa, for patients with lower telomere length ratios, the combined HRs were 0.66 (95%CI, 0.53–0.83) and 0.74 (95%CI, 0.41–1.32) for mortality and tumor progression, respectively. In conclusion, shortened telomere in peripheral blood and tumor tissue might indicate poor survival for cancer patients. However, by calculating the telomere length ratios of tumor tissue to adjacent normal mucosa, the lower ratio might indicate better survival.
. [J]. Frontiers of Medicine, 2016, 10(2): 191-203.
Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature. Front. Med., 2016, 10(2): 191-203.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193): 2011–2015
https://doi.org/10.1126/science.7605428
pmid: 7605428
4
Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H, Siewert JR. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004; 22(10): 1807–1814
https://doi.org/10.1200/JCO.2004.09.160
pmid: 15143073
5
Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406(6796): 641–645
https://doi.org/10.1038/35020592
pmid: 10949306
6
Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28(2): 155–159
https://doi.org/10.1038/88871
pmid: 11381263
7
Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, Svenson U, Roos G, Hosgood HD 3rd, Shen M, Wei Q. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 2011; 6(6): e20466
https://doi.org/10.1371/journal.pone.0020466
pmid: 21695195
8
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93(4): 387–391
https://doi.org/10.1038/sj.bjc.6602678
pmid: 16106245
9
Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 2006; 100(2): 237–238
https://doi.org/10.1007/s10549-006-9253-5
pmid: 16773436
10
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100(2): 229–235
https://doi.org/10.1007/s10549-006-9242-8
pmid: 16932852
11
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8(1): 16
https://doi.org/10.1186/1745-6215-8-16
pmid: 17555582
12
Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54(13): 3557–3560
pmid: 8012981
13
Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, Moyzis R, Griffith J. Association between outcome and telomere DNA content in prostate cancer. J Urol 1999; 162(5): 1788–1792
https://doi.org/10.1016/S0022-5347(05)68239-0
pmid: 10524936
14
Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J. Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade. Breast Cancer Res Treat 2013; 141(2): 231–242
https://doi.org/10.1007/s10549-013-2696-6
pmid: 24036693
15
Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov 2013; 3(10): 1130–1141
https://doi.org/10.1158/2159-8290.CD-13-0135
pmid: 23779129
16
La Torre D, Aguennouz M, Conti A, Giusa M, Raffa G, Abbritti RV, Germano’ A, Angileri FF. Potential clinical role of telomere length in human glioblastoma. Transl Med UniSa 2011; 1: 243–270
pmid: 23905037
17
Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, Allen SL, Kolitz J, Vinciguerra VP, Kudalkar P, Wasil T, Rai KR, Ferrarini M, Gregersen PK, Chiorazzi N. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004; 103(2): 375–382
https://doi.org/10.1182/blood-2003-04-1345
pmid: 14504108
18
Yoon SY, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. Acta Haematol 2007; 118(1): 30–37
https://doi.org/10.1159/000101558
pmid: 17429195
19
Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005; 46(3): 393–399
https://doi.org/10.1080/10428190400018349
pmid: 15621829
20
Sieglová Z, Zilovcová S, Cermák J, Ríhová H, Brezinová D, Dvoráková R, Marková M, Maaloufová J, Sajdová J, Brezinová J, Zemanová Z, Michalová K. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk Res 2004; 28(10): 1013–1021
https://doi.org/10.1016/j.leukres.2003.11.020
pmid: 15289012
21
Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003; 101(12): 4982–4989
https://doi.org/10.1182/blood-2002-11-3451
pmid: 12609839
22
Brümmendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000; 95(6): 1883–1890
pmid: 10706851
23
Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest 2008; 88(2): 144–152
https://doi.org/10.1038/labinvest.3700710
pmid: 18158557
24
Rosenberg R, Gertler R, Stricker D, Lassmann S, Werner M, Nekarda H, Siewert JR. Telomere length and hTERT expression in patients with colorectal carcinoma. Recent Results Cancer Res 2003; 162: 177–181
https://doi.org/10.1007/978-3-642-59349-9_16
pmid: 12790332
25
Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, Matui K, Takada M, Kikui M, Yasumitu T, Ohno A, Nakagawa K, Fukuoka M, Kawase I. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res 2000; 20(3B): 2181–2187
pmid: 10928174
26
Yan S, Han B, Wu Y, Zhou D, Zhao Y. Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia. Leuk Lymphoma 2013; 54(7): 1437–1441
https://doi.org/10.3109/10428194.2012.729834
pmid: 23157242
27
Boscolo-Rizzo P, Rampazzo E, Perissinotto E, Piano MA, Giunco S, Baboci L, Spinato G, Spinato R, Tirelli G, Da Mosto MC, Del Mistro A, De Rossi A. Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncol 2015; 51(5): 500–507
https://doi.org/10.1016/j.oraloncology.2015.02.100
pmid: 25771075
28
Willeit P, Willeit J, Kloss-Brandstätter A, Kronenberg F, Kiechl S. Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. JAMA 2011; 306(1): 42–44
https://doi.org/10.1001/jama.2011.901
pmid: 21730239
29
Kotsopoulos J, Prescott J, De Vivo I, Fan I, Mclaughlin J, Rosen B, Risch H, Sun P, Narod SA. Telomere length and mortality following a diagnosis of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2014; 23(11): 2603–2606
https://doi.org/10.1158/1055-9965.EPI-14-0885
pmid: 25159293
30
Duggan C, Risques R, Alfano C, Prunkard D, Imayama I, Holte S, Baumgartner K, Baumgartner R, Bernstein L, Ballard-Barbash R, Rabinovitch P, McTiernan A. Change in peripheral blood leukocyte telomere length and mortality in breast cancer survivors. J Natl Cancer Inst 2014; 106(4): dju035
https://doi.org/10.1093/jnci/dju035
pmid: 24627273
31
Chen Y, Qu F, He X, Bao G, Liu X, Wan S, Xing J. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann Oncol 2014; 25(4): 869–876
https://doi.org/10.1093/annonc/mdu016
pmid: 24608194
32
Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjærg-Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst 2013; 105(7): 459–468
https://doi.org/10.1093/jnci/djt016
pmid: 23468462
33
Liu HQ, An JZ, Liu J, Yang YF, Zhang HX, Zhao BY, Li JB, Yang HS, Chen ZN, Xing JL. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 2012; 33(5): 1040–1045
https://doi.org/10.1093/carcin/bgs098
pmid: 22318909
34
Shen J, Gammon MD, Terry MB, Bradshaw PT, Wang Q, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival. Breast Cancer Res Treat 2012; 134(1): 393–400
https://doi.org/10.1007/s10549-012-2058-9
pmid: 22527105
35
Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstätter A, Kronenberg F, Kiechl S. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010; 304(1): 69–75
https://doi.org/10.1001/jama.2010.897
pmid: 20606151
36
Svenson U, Ljungberg B, Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res 2009; 69(7): 2896–2901
https://doi.org/10.1158/0008-5472.CAN-08-3513
pmid: 19318563
37
Svenson U, Nordfjäll K, Stegmayr B, Manjer J, Nilsson P, Tavelin B, Henriksson R, Lenner P, Roos G. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 2008; 68(10): 3618–3623
https://doi.org/10.1158/0008-5472.CAN-07-6497
pmid: 18483243
38
Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G. Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer. Cancer Epidemiol Biomarkers Prev 2014; 23(11): 2439–2446
https://doi.org/10.1158/1055-9965.EPI-14-0228
pmid: 25234236
39
Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, Cinciripini PM, Wu X. Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev 2015; 24(2): 336–343
https://doi.org/10.1158/1055-9965.EPI-14-0992
pmid: 25416716
40
Chen Y, Wu Y, Huang X, Qu P, Li G, Jin T, Xing J, He S. Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients. J Cancer Res Clin Oncol 2015; 141(10): 1739–1747
https://doi.org/10.1007/s00432-015-1938-x
pmid: 25702101
41
Qu F, Li R, He X, Li Q, Xie S, Gong L, Ji G, Lu J, Bao G. Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients. Mol Oncol 2015; 9(3): 727–739
https://doi.org/10.1016/j.molonc.2014.11.008
pmid: 25515040
42
Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, Bailey J, Cawkwell L, Hills R, Grimstead JW, Jones RE, Britt-Compton B, Fegan C, Baird DM, Pepper C. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol 2014; 167(2): 214–223
https://doi.org/10.1111/bjh.13023
pmid: 24990087
43
Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, Smedby KE, Geisler C, Juliusson G, Roos G, Rosenquist R. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 2013; 88(8): 647–651
https://doi.org/10.1002/ajh.23466
pmid: 23620080
44
Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, Frezzato F, Facco M, Novella E, Giaretta I, Del Bianco P, Semenzato G, De Rossi A. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 2012; 97(1): 56–63
https://doi.org/10.3324/haematol.2011.049874
pmid: 21933855
45
Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, Baerlocher GM, Röth A. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 2011; 93(1): 74–82
https://doi.org/10.1007/s12185-010-0750-2
pmid: 21203871
46
Rossi D, Bodoni CL, Zucchetto A, Rasi S, De Paoli L, Fangazio M, Rossi FM, Ladetto M, Gattei V, Gaidano G. Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. Am J Hematol 2010; 85(8): 619–622
https://doi.org/10.1002/ajh.21756
pmid: 20578200
47
Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M. Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009; 23(6): 1062–1072
https://doi.org/10.1038/leu.2008.399
pmid: 19340005
48
Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, Rosenquist R, Stilgenbauer S. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111(4): 2246–2252
https://doi.org/10.1182/blood-2007-05-092759
pmid: 18045969
49
Ghaffari SH, Shayan-Asl N, Jamialahmadi AH, Alimoghaddam K, Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 2008; 19(11): 1927–1934
https://doi.org/10.1093/annonc/mdn394
pmid: 18567608
50
Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007; 21(4): 697–705
pmid: 17301820
51
Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, Stark B, Ash S, Cohen IJ, Meller I, Kollender Y, Issakov J, Yaniv I. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res 2007; 13(19): 5777–5783
https://doi.org/10.1158/1078-0432.CCR-07-0308
pmid: 17908968
52
Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, Laurell A, Sundström C, Rosenquist R, Roos G. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105(12): 4807–4812
https://doi.org/10.1182/blood-2004-11-4394
pmid: 15746080
53
Rigolin GM, Porta MD, Bugli AM, Castagnari B, Mauro E, Bragotti LZ, Ciccone M, Cuneo A, Castoldi G. Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. Eur J Haematol 2004; 73(5): 351–358
https://doi.org/10.1111/j.1600-0609.2004.00305.x
pmid: 15458514
54
Hultdin M, Rosenquist R, Thunberg U, Tobin G, Norrback KF, Johnson A, Sundström C, Roos G. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003; 88(4): 593–598
https://doi.org/10.1038/sj.bjc.6600763
pmid: 12592375
55
Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res 1998; 58(21): 4918–4922
pmid: 9810000
Spanoudakis E, Bazdiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, Xanthopoulidis G, Moustakidis E, Mantzourani S, Bourikas G, Tsatalas C. Dynamics of telomere’s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res 2011; 35(4): 459–464
https://doi.org/10.1016/j.leukres.2010.07.042
pmid: 20828816
58
Borssén M, Cullman I, Norén-Nyström U, Sundström C, Porwit A, Forestier E, Roos G. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. Exp Hematol 2011; 39(12): 1144–1151
https://doi.org/10.1016/j.exphem.2011.08.014
pmid: 21914494
59
Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TF, Möller P, Zenz T, Döhner H, Stilgenbauer S. Telomere length in mantle cell lymphoma. Blood 2013; 121(7): 1184–1187
https://doi.org/10.1182/blood-2012-08-452649
pmid: 23243283
60
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res 2011; 13(3): R56
https://doi.org/10.1186/bcr2893
pmid: 21645396
61
Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res 2007; 13(23): 7037–7043
https://doi.org/10.1158/1078-0432.CCR-07-0432
pmid: 18056180
62
Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, Zaizov R, Yaniv I. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006; 107(6): 1391–1399
https://doi.org/10.1002/cncr.22132
pmid: 16917952
63
Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 2006; 99(2): 193–202
https://doi.org/10.1007/s10549-006-9204-1
pmid: 16752076
64
Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006; 106(3): 541–551
https://doi.org/10.1002/cncr.21625
pmid: 16388518
65
Patel MM, Parekh LJ, Jha FP, Sainger RN, Patel JB, Patel DD, Shah PM, Patel PS. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002; 24(12): 1060–1067
https://doi.org/10.1002/hed.10169
pmid: 12454944
66
Jeon HS, Choi YY, Choi JE, Lee WK, Lee E, Yoo SS, Lee SY, Lee J, Cha SI, Kim CH, Park JY. Telomere length of tumor tissues and survival in patients with early stage non-small cell lung cancer. Mol Carcinog 2014; 53(4): 272–279
https://doi.org/10.1002/mc.21972
pmid: 23065897
67
Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 2015; 112(2): 313–318
https://doi.org/10.1038/bjc.2014.561
pmid: 25412235
68
Pezzolo A, Pistorio A, Gambini C, Haupt R, Ferraro M, Erminio G, De Bernardi B, Garaventa A, Pistoia V. Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget 2015; 6(10): 7493–7503
https://doi.org/10.18632/oncotarget.2115
pmid: 25595889
69
Zhang DH, Chen JY, Hong CQ, Yi DQ, Wang F, Cui W. High-risk human papillomavirus infection associated with telomere elongation in patients with esophageal squamous cell carcinoma with poor prognosis. Cancer 2014; 120(17): 2673–2683
https://doi.org/10.1002/cncr.28797
pmid: 24840723
70
Kuhn E, Meeker AK, Visvanathan K, Gross AL, Wang TL, Kurman RJ, Shih IeM. Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod Pathol 2011; 24(8): 1139–1145
https://doi.org/10.1038/modpathol.2011.67
pmid: 21499239
71
Valls C, Piñol C, Reñé JM, Buenestado J, Viñas J. Telomere length is a prognostic factor for overall survival in colorectal cancer. Colorectal Dis 2011; 13(11): 1265–1272
https://doi.org/10.1111/j.1463-1318.2010.02433.x
pmid: 20874798
72
Baydar DE, Ozen H, Geyik PO, Gurel B. Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study. Pathol Res Pract 2010; 206(10): 700–704
https://doi.org/10.1016/j.prp.2010.05.009
pmid: 20674190
73
Gertler R, Doll D, Maak M, Feith M, Rosenberg R. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer 2008; 112(10): 2173–2180
https://doi.org/10.1002/cncr.23419
pmid: 18348304
74
Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, Hernando F, López-Asenjo JA, Torres AJ, Benito M, Iniesta P. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 2008; 60(3): 416–425
https://doi.org/10.1016/j.lungcan.2007.11.001
pmid: 18077053
75
Sainger RN, Telang SD, Shukla SN, Patel PS. Clinical significance of telomere length and associated proteins in oral cancer. Biomark Insights 2007; 2: 9–19
pmid: 19662189
76
Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol 2005; 11(44): 6941–6947
https://doi.org/10.3748/wjg.v11.i44.6941
pmid: 16437597
77
Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112(1): 44–50
https://doi.org/10.1002/ijc.20279
pmid: 15305374
78
Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro-oncol 2013; 15(4): 423–432
https://doi.org/10.1093/neuonc/nos329
pmid: 23393205
79
Hsu CP, Miaw J, Shai SE, Chen CY. Correlation between telomerase expression and terminal restriction fragment length ratio in non-small cell lung cancer—an adjusted measurement and its clinical significance. Eur J Cardiothorac Surg 2004; 26(2): 425–431
https://doi.org/10.1016/j.ejcts.2004.04.029
pmid: 15296909
80
Zhang C, Chen X, Li L, Zhou Y, Wang C, Hou S. The association between telomere length and cancer prognosis: evidence from a meta-analysis. PLoS ONE 2015; 10(7): e0133174
https://doi.org/10.1371/journal.pone.0133174
pmid: 26177192